Case Studies of Ibogaine Treatment: Implications for Patient Management Strategies
Outcomes Case series high
AI-extracted · unverified · confirm at source
Three case studies across drug user, self-help, and clinical settings document opioid withdrawal attenuation and craving reduction; richer oneirophrenic experiences correlate with longer drug-free periods.
Dosing: 0.14–19 mg/kg oral (1962 group); 100 mg test dose + 1200 mg therapeutic (ICASH, ~1989); 100 mg + 25 mg test doses, 10 mg/kg experimental, 20 mg/kg therapeutic (Panama clinical) (oral)
Sample size: 5